Search

21 Jul 2023: Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53..

20 May 2024: Alan Fersht - Tumour suppressor p53 structure and drug discovery.

21 Jul 2023: Tumour suppressor p53 structure and drug discovery. LMB Division - Protein and Nucleic Acid Chemistry.

{"id":21808,"date":"2021-11-24T16:17:22","date_gmt":"2021-11-24T16:17:22","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=21808"},"modified":"2024-04-12T12:09:08","modified_gmt":"2024-04-12T11:09:08","slug":"how-dna-damage-induces-appetite-supp

{"id":61,"date":"2012-06-25T10:03:42","date_gmt":"2012-06-25T10:03:42","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/?page_id=61"},"modified":"2024-05-20T14:39:16","modified_gmt":"2024-05-20T13:39:16","slug":"protein-and-nucleic-acid-ch

26 Jan 2021: Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... Tumour Suppressor p53. Structural Biology and Drug Discovery. Alan Fersht. MRC Laboratory of Molecular Biology.

n. Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... We discovered that about 30% of oncogenic mutants of p53 are just temperatures sensitive and can, in theory, be rescued by small molecules.

{"id":11414,"date":"2018-01-04T09:33:03","date_gmt":"2018-01-04T09:33:03","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/?p=11414"},"modified":"2020-11-19T16:55:54","modified_gmt":"2020-11-19T16:55:54","slug":"uncovering-alcohol-derived-metabolite

n. Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of u20ac1.5m for his project u201cTumour suppressor p53: structure, stability and ... 70% of human cancers have p53 directly inactivated by mutation.

can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

20 Oct 2017: can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

{"id":10488,"date":"2017-05-11T09:38:13","date_gmt":"2017-05-11T08:38:13","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/?p=10488"},"modified":"2019-10-24T14:30:10","modified_gmt":"2019-10-24T13:30:10","slug":"dynamic-structure-human-dna-repair-en

3 May 2024: Valle (2011) "Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA".

2 Jun 2011: Second row: p53 group members and Alan cutting cake.Third row: Ada Yonath, Hualiang Jiang, Jianpeng Ma and Sarah Perrett. ... Fourth row: Amnon Horovitz, Qinghua Wan and p53 group members; Bottom row: Qinghua Wang, Marilyn Fersht, Qinghua Wang, Jianpeng

{"id":18741,"date":"2020-08-04T17:10:07","date_gmt":"2020-08-04T16:10:07","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=18741"},"modified":"2020-08-04T17:10:09","modified_gmt":"2020-08-04T16:10:09","slug":"alan-fersht-and-marta-zlatic-win-roy

26 Nov 2010: Alan’s grant complements his MRC programme grant on the “Structural Biology of p53”, which started on 1 October 2010. ... 70% of human cancers have p53 directly inactivated by mutation. Alan’s group has found that some 30% of the inactivated

In additional experiments we were able to cage a key lysine in a nuclear localization signal in p53, and define the contribution of that signal to the kinetics of nuclear import.

4 Jan 2018: This result suggests that the critically important p53 stress response in stem cells fundamentally differ from the response seen in other cells. ... In addition, the new insight into the function of p53 in blood stem cells may explain why certain blood

11 May 2017: the damage, including arresting the cell cycle by phosphorylating the checkpoint kinase CHK2 and, under some conditions, inducing apoptosis by phosphorylating p53 and preventing its degradation. ... Using p53 produced by Tomas Kouba in Alan Fersht’s